<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Why This Biotech Company Could Be a Growth Stock Powerhouse — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Why This Biotech Company Could Be a Growth Stock Powerhouse</h2>
    <div class="badge">2025-09-17T09:10:00+00:00</div>
    <ul>
      <li>But, back in 2019, Vertex won approval for Trikafta, a treatment that may be used for up to 90% of CF patients.</li>
<li>if you invested $1,000 at the time of our recommendation, you’d have $648,369 !* Or when Nvidia made this list on April 15, 2005...</li>
<li>if you invested $1,000 at the time of our recommendation, you’d have $1,089,583 !* Now, it’s worth noting Stock Advisor’s total average return is 1,060 % — a market-crushing outperformance compared to 189% for the S&amp;P 50</li>
<li>Consider when Netflix made this list on December 17, 2004...</li>
<li>(Vertex also has rewarded long-term investors, as the stock has climbed about 190% over the past decade.) VRTX Revenue (Annual) Chart VRTX Revenue (Annual) data by YCharts In CF, symptoms are caused by a malfunctioning p</li>
<li>The 10 stocks that made the cut could produce monster returns in the coming years.</li>
<li>Don’t miss out on the latest top 10 list, available when you join Stock Advisor .</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Why This Biotech Company Could Be a Growth Stock Powerhouse
• But, back in 2019, Vertex won approval for Trikafta, a treatment that may be used for up to 90% of CF patients.
• if you invested $1,000 at the time of our recommendation, you’d have $648,369 !* Or when Nvidia made this list on April 15, 2005...
• if you invested $1,000 at the time of our recommendation, you’d have $1,089,583 !* Now, it’s worth noting Stock Advisor’s total average return is 1,060 % — a market-crushing outperformance compared to 189% for the S&amp;P 50
• Consider when Netflix made this list on December 17, 2004...
• (Vertex also has rewarded long-term investors, as the stock has climbed about 190% over the past decade.) VRTX Revenue (Annual) Chart VRTX Revenue (Annual) data by YCharts In CF, symptoms are caused by a malfunctioning p
• The 10 stocks that made the cut could produce monster returns in the coming years.
• Don’t miss out on the latest top 10 list, available when you join Stock Advisor ." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;<a class="btn" href="https://finance.yahoo.com/m/77236724-cf23-396f-8090-677de39b0035/why-this-biotech-company.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>